The Efficacy and Safety of Hetrombopag as Secondary Prevention to Chemotherapy-induced Thrombocytopenia in Patients With Gynecologic Malignancies

NCT06099925 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Chemotherapy-induced Thrombocytopenia

Interventions

DRUG: Hetrombopag

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University